BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21621630)

  • 1. Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.
    Reddy N; Savani BN
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1265-72. PubMed ID: 21621630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma.
    Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.
    Reddy NM; Oluwole O; Greer JP; Engelhardt BG; Jagasia MH; Savani BN
    Exp Hematol; 2014 Jan; 42(1):39-45. PubMed ID: 24096123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation.
    Reddy N; Oluwole O; Greer JP; Goodman S; Engelhardt B; Jagasia MH; Savani BN
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):406-11. PubMed ID: 22981964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
    Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
    Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
    Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
    Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
    Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
    Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplantation for follicular lymphoma: optimal timing and indication.
    Kim SW
    J Clin Exp Hematop; 2014; 54(1):39-47. PubMed ID: 24942945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma.
    Crocchiolo R; Castagna L; Fürst S; El-Cheikh J; Faucher C; Oudin C; Granata A; Bouabdallah R; Coso D; Chabannon C; Balzarotti M; Santoro A; Blaise D
    Bone Marrow Transplant; 2013 Feb; 48(2):249-52. PubMed ID: 22732704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
    Bhatt VR; Vose JM
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
    Fenske TS; Hamadani M; Cohen JB; Costa LJ; Kahl BS; Evens AM; Hamlin PA; Lazarus HM; Petersdorf E; Bredeson C
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1543-1551. PubMed ID: 27131863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
    Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
    Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
    Maloney DG
    Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation.
    Yoshimi A; Izutsu K; Takahashi M; Kako S; Oshima K; Kanda Y; Motokura T; Chiba S; Momose T; Ohtomo K; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):477-81. PubMed ID: 18266206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation for non-Hodgkin lymphoma.
    Nademanee A
    Expert Rev Hematol; 2009 Aug; 2(4):425-42. PubMed ID: 21082947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation.
    Kim JW; Kim BS; Bang SM; Kim I; Kim DH; Kim WS; Yang DH; Lee JJ; Lee JH; Kim JS; Sohn SK; Yhim HY; Kwak JY; Yoon SS; Lee JS; Park S; Kim BK;
    Ann Hematol; 2011 Dec; 90(12):1409-18. PubMed ID: 21468694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
    Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
    Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
    Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
    Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.